title: [The role of direct-acting P2Y12 inhibitors in acute coronary syndrome].
abstract: P2Y12 receptor inhibitors are recommended for treatment of patients with acute coronary syndrome and/or percutaneous coronary intervention as a part of dual antiplatelet therapy. While thienopyridine group of P2Y12 inhibitors remains to be widely used treatment for patients with ACS, there are still complications for its application. Emerging antiplatelet treatments expand therapy strategies for management of ACS. The purpose of this article is to define the developing role of novel non-thienopyridine reversible P2Y12 inhibitor ticagrelor  to present its pharmacokinetic, pharmacodynamic, and pharmacogenetic characteristics, based on current evidence.
authors: T A
authors: TA
authors: Buriakina
authors: D A
authors: DA
authors: Zateĭshchikov
mesh_terms: D054058:Acute Coronary Syndrome / Q000097:blood / Q000188:drug therapy / Q000235:genetics; D001711:Biotransformation / Q000235:genetics; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002986:Clinical Trials as Topic; D004347:Drug Interactions; D006801:Humans; D010597:Pharmacogenetics; D060735:Pharmacovigilance; D015539:Platelet Activation / Q000187:drug effects / Q000235:genetics; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D058921:Purinergic P2Y Receptor Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use; D058925:Receptors, Purinergic P2Y12 / Q000235:genetics
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D058925:Receptors, Purinergic P2Y12